Your browser doesn't support javascript.
loading
Advances in radiotherapy and its impact on second primary cancer risk: A multi-center cohort study in prostate cancer patients.
Jahreiß, Marie-Christina; Hoogeman, Mischa; Aben, Katja Kh; Dirkx, Maarten; Snieders, Renier; Pos, Floris J; Janssen, Tomas; Dekker, Andre; Vanneste, Ben; Minken, Andre; Hoekstra, Carel; Smeenk, Robert J; Incrocci, Luca; Heemsbergen, Wilma D.
Afiliação
  • Jahreiß MC; Department of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.
  • Hoogeman M; Department of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.
  • Aben KK; Department of Research & Development, Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands; Department for Health Evidence, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Dirkx M; Department of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.
  • Snieders R; Department of Research & Development, Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands.
  • Pos FJ; Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Janssen T; Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Dekker A; Department of Radiation Oncology (Maastro), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, the Netherlands.
  • Vanneste B; Department of Radiation Oncology (Maastro), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Human Structure and Repair; Department of Radiation Oncology, Ghent University Hospital, Belgium.
  • Minken A; Radiotherapiegroep, Institute of Radiation Oncology, Arnhem/Deventer, the Netherlands.
  • Hoekstra C; Radiotherapiegroep, Institute of Radiation Oncology, Arnhem/Deventer, the Netherlands.
  • Smeenk RJ; Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Incrocci L; Department of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.
  • Heemsbergen WD; Department of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands. Electronic address: w.heemsbergen@erasmusmc.nl.
Radiother Oncol ; 183: 109659, 2023 06.
Article em En | MEDLINE | ID: mdl-37003369
ABSTRACT

BACKGROUND:

Modelling studies suggest that advanced intensity-modulated radiotherapy may increase second primary cancer (SPC) risks, due to increased radiation exposure of tissues located outside the treatment fields. In the current study we investigated the association between SPC risks and characteristics of applied external beam radiotherapy (EBRT) protocols for localized prostate cancer (PCa).

METHODS:

We collected EBRT protocol characteristics (2000-2016) from five Dutch RT institutes for the 3D-CRT and advanced EBRT era (N = 7908). From the Netherlands Cancer Registry we obtained patient/tumour characteristics, SPC data, and survival information. Standardized incidence ratios (SIR) were calculated for pelvis and non-pelvis SPC. Nationwide SIRs were calculated as a reference, using calendar period as a proxy to label 3D-CRT/advanced EBRT.

RESULTS:

From 2000-2006, 3D-CRT with 68-78 Gy in 2 Gy fractions, delivered with 10-23 MV and weekly portal imaging was the most dominant protocol. By the year 2010 all institutes routinely used advanced EBRT (IMRT, VMAT, tomotherapy), mainly delivering 78 Gy in 2 Gy fractions, using various kV/MV imaging protocols. Sixteen percent (N = 1268) developed ≥ 1 SPC. SIRs for pelvis and non-pelvis SPC (all institutes, advanced EBRT vs 3D-CRT) were 1.17 (1.00-1.36) vs 1.39 (1.21-1.59), and 1.01 (0.89-1.07) vs 1.03 (0.94-1.13), respectively. Nationwide non-pelvis SIR was 1.07 (1.01-1.13) vs 1.02 (0.98-1.07). Other RT protocol characteristics did not correlate with SPC endpoints.

CONCLUSION:

None of the studied RT characteristics of advanced EBRT was associated with increased out-of-field SPC risks. With constantly evolving EBRT protocols, evaluation of associated SPC risks remains important.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Segunda Neoplasia Primária / Radioterapia Conformacional / Radioterapia de Intensidade Modulada Tipo de estudo: Clinical_trials / Etiology_studies / Guideline / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Radiother Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Segunda Neoplasia Primária / Radioterapia Conformacional / Radioterapia de Intensidade Modulada Tipo de estudo: Clinical_trials / Etiology_studies / Guideline / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Radiother Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Holanda